X4 Pharmaceuticals Inc
Research X4 Pharmaceuticals Inc (XFOR) on Bullrun: market cap USD 399.84M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXFOR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 399.84M
- Financial periodQ2 2026
- RevenueUSD 8.81M
- Net income-USD 16.16M
- Free cash flow-USD 25.79M
- Gross margin81.6%
Valuation Snapshot
latest market cap is USD 399.84M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 35.11M | -USD 79.20M | -USD 85.62M | 83.6% | -1.87 | USD 217.05M | USD 75.00M | USD 186.29M |
| FY2024 | USD 2.56M | -USD 37.45M | -USD 131.23M | 68.8% | -5.59 | USD 55.70M | USD 75.00M | USD 22.15M |
| FY2023 | USD 0 | -USD 101.17M | -USD 96.57M | n/a | -17.07 | USD 99.22M | USD 54.57M | USD 51.10M |
| FY2022 | USD 0 | -USD 93.87M | -USD 77.21M | n/a | -1.52 | USD 121.72M | USD 33.62M | USD 74.05M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 399.84M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 363.63M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 125.47M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 140.36M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 120.69M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 64.41M | n/a | n/a | n/a |
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is X4 Pharmaceuticals Inc's market cap?
X4 Pharmaceuticals Inc's market capitalization is USD 399.84M.
What does X4 Pharmaceuticals Inc do?
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd.